Journal of Clinical Medicine
Renoprotective vs. Antihypertensive Dosing of Renin–Angiotensin System Inhibitors in Chronic Kidney Disease: Analysis of Summary of Product Characteristics of Medicinal Products Authorized in Poland
By Marta Maciejczyk, Anna Maria Dworakowska and Magdalena Bujalska-Zadrożny.
Abstract
Introduction
Renin–angiotensin system inhibitors are central to antihypertensive and nephroprotective treatment in chronic kidney disease. However, renal dosing information in Summaries of Product Characteristics (SmPCs) may differ between products and may not reflect current kidney function assessment.
Objectives
We systematically evaluated dosing recommendations for single-component ACE inhibitors and angiotensin receptor blockers authorized in Poland, focusing on renal impairment and nephroprotective indications. Patients and methods: This cross-sectional content analysis included SmPCs for medicinal products classified under ATC codes C09AA and C09CA. Documents were retrieved from Polish and European regulatory sources. Data were extracted on indications, antihypertensive and nephroprotective dosing, renal dose-adjustment recommendations, renal function parameters, estimation formulas, thresholds, dose limits, and dialysis-related statements.